As IFN-γ release ELISpot is increasingly used for drug causality assessment in patients with life-threatening, severe immune-mediated adverse drug reactions (IM-ADRs), ELISpot has been shown to be an efficient ex vivo tool in the diagnosis of antibiotic-associated SCAR patients (Trubiano et al., 2018) by offering the benefit of observing the patient’s reaction to a drug without re-exposing the patient. The gene discussed is IFNG; the disease is Scarring.